Noncoding RNA expression profiling in mouse PTEN-deficient prostate cancer as a potential biomarker

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K11165
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Kindai University
• Principal Investigator: DE VELASCO Marco 近畿大学, 医学部, 助教 (20449838)
• Co-Investigator(Kenkyū-buntansha): 植村 天受 近畿大学, 医学部, 教授 (90213397)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 前立腺癌 / ノンコーディングRNA / バイオマーカー / 遺伝子改変マウスモデル

Outline of Final Research Achievements

We previously showed that androgen withdrawal led to increased alternatively spliced products in our originally established mouse prostate tumors. Here, we perform gene expression analysis this mouse prostate cancer model to identify candidate mRNA processing genes implicated in the progression to castration-resistant disease. Affymetrix GeneChip mouse transcriptome assay to perform comparative analysis of the transcriptomes of normal prostate tissue and PTEN-deficient castration-naïve, castration-sensitive prostate cancers. Clustering analysis revealed genes enriched with the functions involved in mRNA splicing and processing in mice with prostate tumors. Of these. We focused on NEAT1（encoding nuclear paraspeckle assembly transcript 1）and investigated anti-tumor effects using our mouse prostate cancer model. A part of the date was reported at JCA and AACR meetings.

Free Research Field

泌尿器腫瘍学

Academic Significance and Societal Importance of the Research Achievements

我々が開発した前立腺癌マウスモデルは、ヒト前立腺癌の自然史と同様の発生・進展を示し、CRPCモデルにおいてもAR発現プロファイルが酷似していることから、様々な前臨床試験での検証を可能にしてきただけでなく、分子レベルの基礎研究を飛躍的に転換させるものである。今回の新たなアプローチで同定される新規標的分子をスピーディーに検証できる意義は大きく、知的財産等につながることができれば医学的に極めて重要なメリットとなるであろう。